Skip to main content
. 2014 Feb 21;20(7):1858–1870. doi: 10.3748/wjg.v20.i7.1858

Table 3.

Case-control studies included in the meta-analysis

Study Study location All subjects CRC cases OR 95%CI Control for potential confounding factors2
Deshpande[62], 2013 United States 73472 36736 0.96 0.89-1.05 1-4
Broughton et al[64], 2012 United Kingdom 233 101 0.43 0.25-0.80 1, 2, 5-8
Lakha et al[63], 2012 United Kingdom 603 309 0.33 0.15-0.69 1-3, 9-15
Cheng et al[65], 2011 Taiwan 5780 1156 1.09 0.91-1.30 1-3, 5, 8, 9, 16-21
Vinogradova et al[26], 2011 United Kingdom 60373 11749 1.07 1.00-1.15 1-3, 7, 9, 11, 12, 22-27
Robertson et al[66], 2010 Denmark 109769 9979 0.87 0.80-0.96 1, 2, 5-7, 9, 10, 19
Hachem et al[68], 2009 United States 30400 6080 0.91 0.86-0.96 1-4, 9, 16, 19, 20, 28, 29
Shadman et al[67], 2009 United States 2044 669 1.17 0.74-1.85 1, 4, 11, 12, 30-33
Boudreau et al[70], 2008 United States 1330 665 1.02 0.65-1.59 1, 2, 5, 9, 11, 12, 32
Yang et al[69], 2008 United Kingdom 48724 4432 1.10 0.50-2.20 1, 2, 4, 6, 7, 9, 11, 12, 32, 34
Hoffmeister et al[71], 2007 Germany 1154 540 0.69 0.45-1.06 1, 2, 4-7, 9, 11, 12, 30-32, 35-37
Coogan et al[72], 2007 United States 3618 1809 0.92 0.78-1.09 1, 2, 4, 9, 10
Li et al[73], 2006 United States 741 3391 0.8 0.34-1.87 1, 2, 5, 6, 9, 11, 12, 30, 38
Poynter et al[25], 2005 Israel 3968 1953 0.53 0.38-0.74 1, 2, 9, 30, 36, 39-41
Rubin et al[74], 2005 United States 387240 18440 0.92 0.89-0.96 1, 2, 4, 9, 17, 42-45
Kaye et al[76], 2004 United Kingdom 18088 3291 1.0 0.6-1.7 1, 2, 11, 12, 42
Graaf et al[77], 2004 Netherlands 20105 2921 0.87 0.48-1.57 1, 2, 5, 9, 17, 18, 32, 34, 46-49
Khurana et al[75], 2004 United States 534273 53391 0.94 0.89-1.00 1, 2, 6, 9, 12, 38, 50
Blais et al[78], 2000 Canada 5962 561 0.83 0.37-1.89 1, 2, 14, 18, 34, 46
1

Figures for colon cancer rather than colorectal cancer;

2

1: Age; 2: Sex; 3: Inflammatory bowel disease; 4: Colonoscopy; 5: Diabetes; 6: Alcohol use; 7: Use of aspirin; 8: Use of metformin; 9: Use of NSAIDs; 10: Precinct of residence; 11: Body mass index; 12: Smoking status; 13: Physical activity level; 14: History of neoplasia; 15: Family history of cancer; 16: Fecal occult blood; 17: Prior hospitalizations; 18: Other lipid-lowering therapy; 19: Cholecystectomy; 20: Liver disease; 21: Colorectal polyps; 22: History of heart attack; 23: Hypertension; 24: Coronary heart disease; 25: Socioeconomic status; 26: Rheumatoid arthritis; 27: Use of COX-2 inhibitors; 28: Diabetic nephropathy; 29: Use of sulfonylurea; 30: Family history of colorectal cancer; 31: Education; 32: Hormone replacement therapy; 33: Calendar year; 34: Duration of follow-up; 35: Red meat consumption; 36: Hypercholesterolemia; 37: History of rheumatic disease; 38: Race; 39: Ethnic group; 40: Sports participation; 41: Level of vegetable consumption; 42: Number of physician visits; 43: Use of glucocorticosteroids; 44: Use of immunomodulators; 45: Use of 5-aminosalicylic acids; 46: Comorbidity score; 47: Use of diuretics; 48: Use of ACE inhibitors; 49: Use of CCBs; 50: Obesity. CRC: Colorectal cancer.

HHS Vulnerability Disclosure